Skip to content
  • Research
  • Open Access

Promiscuous prediction and conservancy analysis of CTL binding epitopes of HCV 3a viral proteome from Punjab Pakistan: an In Silico Approach

Virology Journal20118:55

https://doi.org/10.1186/1743-422X-8-55

©  Shehzadi et al; licensee BioMed Central Ltd. 2011

  • Received: 25 January 2011
  • Accepted: 8 February 2011
  • Published:

Abstract

Background

HCV is a positive sense RNA virus affecting approximately 180 million people world wide and about 10 million Pakistani populations. HCV genotype 3a is the major cause of infection in Pakistani population. One of the major problems of HCV infection especially in the developing countries that limits the limits the antiviral therapy is the long term treatment, high dosage and side effects. Studies of antigenic epitopes of viral sequences of a specific origin can provide an effective way to overcome the mutation rate and to determine the promiscuous binders to be used for epitope based subunit vaccine design. An in silico approach was applied for the analysis of entire HCV proteome of Pakistani origin, aimed to identify the viral epitopes and their conservancy in HCV genotypes 1, 2 and 3 of diverse origin.

Results

Immunoinformatic tools were applied for the predictive analysis of HCV 3a antigenic epitopes of Pakistani origin. All the predicted epitopes were then subjected for their conservancy analysis in HCV genotypes 1, 2 and 3 of diverse origin (worldwide). Using freely available web servers, 150 MHC II epitopes were predicted as promiscuous binders against 51 subjected alleles. E2 protein represented the 20% of all the predicted MHC II epitopes. 75.33% of the predicted MHC II epitopes were (77-100%) conserve in genotype 3; 47.33% and 40.66% in genotype 1 and 2 respectively. 69 MHC I epitopes were predicted as promiscuous binders against 47 subjected alleles. NS4b represented 26% of all the MHC I predicted epitopes. Significantly higher epitope conservancy was represented by genotype 3 i.e. 78.26% and 21.05% for genotype 1 and 2.

Conclusions

The study revealed comprehensive catalogue of potential HCV derived CTL epitopes from viral proteome of Pakistan origin. A considerable number of predicted epitopes were found to be conserved in different HCV genotype. However, the number of conserved epitopes in HCV genotype 3 was significantly higher in contrast to its conservancy in HCV genotype 1 and 2. Despite of the lower conservancy in genotype 1 and 2, all the predicted epitopes have important implications in diagnostics as well as CTL-based rational vaccine design, effective for most population of the world and especially the Pakistani Population.

Keywords

  • Epitope Prediction
  • Amino Acid Group
  • Anchor Residue
  • Pakistani Population
  • Pakistani Origin

Background

Family Flaviviridae comprises small enveloped pathogens classified in three genera: Flavivirus, Pestivirus, and Hepacivirus. Members of these genera cause various diseases in humans and other animals such as birds, horses and pigs. The only genera Flavivirus contain more than 70 members including Hepatitis C Virus (HCV), Dengue virus, West Nile virus and tick-borne encephalitis virus [1–3].

HCV is a positive sense RNA virus affecting approximately 180 million people world wide and rate of infection in Pakistani population is about 10 million [4, 5]. HCV genome contributes about 9400 nucleotides that encode single polyprotein of approximately 3010 to 3033 amino acids in length [6]. This single polyprotein is processed by viral as well as host proteases into three structural proteins (i.e. core, E1 and E2) and four non-structural proteins (i.e. NS2, NS3, NS4, and NS5A) [7].

HCV mainly spreads via blood supply, reuse of glass syringes and needles, unsterilized medical equipment, use of tooth brushes of HCV patients, etc [7] and causes of acute and chronic infections [8]. Clinical demonstrations of acute Hepatitus C Viral infection include Jaundice, Fever, Myalgia, Fatigue, Lethargy, Increased ALT, Anorexia and Fulminant hepatic failure [7]. About 80% of HCV infected individuals develop chronic infections [9]. Chronic liver infections develop chronic hepatitis, cirrhosis and hepatocellular carcinoma within a period of 10, 20 and 30 years respectively followed by viral infection [10, 11]. Out of 70-80% chronically infected individuals, 20% develop cirrhosis and 1-5% individuals suffer from final stage of liver diseases [12]. Hepatic steatosis is the accumulation of lipids in hepatocytes and is reported for the cause of cirrhosis [13] with the more severe cases being reported in patients infected with HCV genotype 3a [14]. The prevelance of steatosis in Pakistani population is about 61.5-65.5% compared with 32.8-81.2% in western countries [15]. The percentage of males infected with HCV chronic liver stage is higher then females with the age of patients between 40-50 years [5].

HCV is classified into six genotypes each heaving various subtypes [16–18]. These genotypes are distributed differently in various parts of the world with the genetic variance between them is about one third. The genotypes 1, 2 and 3 have world wide distribution. But the significant differences are observed in subtype distribution. Subtype 1a is mostly found in North America and Europe followed by 2b and 3a. Subtype 1b is frequently found in South East Europe and Tunisia and 2c in North Italy. Genotype 4 is mainly restricted to Middle East and Central Africa and genotype 5 in South Africa. Genotype 6 is distributed throughout South East Asia and also being isolated from Hong Kong and Vietnam [17]. The most frequent HCV genotypic distribution in Pakistan is 3a [49.05%] followed by 3b [17.66%] [19]. The knowledge of HCV distribution is crucial for treatment therapy and vaccination because of its predictive value in terms of response to antiviral therapy and vaccination. Effective responses to antiviral therapy are normally associated with genotype 2 and 3 in comparison to any other genotype [20].

HCV replicates at about 1012 new HCV viruses/day. Replication is carried out by RNA dependent RNA polymerase. RNA polymerase lacks the "proofreading" ability that ensures the high mutation rate of about 8-18 mutations in genomic RNA/year [21, 20]. Such a high mutation rate limits the treatment therapy and vaccination. The current treatment therapy for HCV is INF alpha along with ribavirin limited to about 50% population [22]. Although the response rate is not much deterring, but high dosage, long-term treatment and side effects limits the usage [23, 21]. There is the possibility that after next few years, new antiviral agents such as inhibitors of the viral protease, helices or polymerase will further improve the response rate of the current therapeutic agents. However, antiviral therapy is not affordable in most developing countries, where the prevalence of HCV is generally the highest. Thus, given the huge reservoir of HCV worldwide, the development of an effective vaccine may be the cheapest way to control disease associated with HCV infection.

Development of an effective HCV vaccine requires understanding of immune response. Viral immune response is associated with Major Histocompatabiliy complex protein (MHC) and T lymphocytes/T cell. MHC are classified into 2 broad categories, MHC I and MHC II [24]. MHC initially recognizes the viral antigenic epitopes and presents to T lymphocytes for degradation. MHC I presents the antigenic epitopes to CD8+ T cells and MHC II presents to CD4+ T cells for viral degradation [25, 26]. CD8 T cells also referred to as cytotoxic T cells (CTL or Tc), limit viral infections by initial recognizing and their subsequent killing infected cells and secreting cytokines. CD4 T referred to as helper cells or Th cells and provides growth factors and signals for generation and maintenance of CD8 T cells [27]. T cells recognize the antigens only when they are associated with MHC, surface glycoprotein exposed on surface of all vertebrate cells. The selection of T cell epitopes is also important because these are linear and hence easy to synthesize.

A particular vaccine developed against HCV can't be effective for Pakistani population because of variations in HCV genomic sequences and distribution with regard to geographical area. Since a large number of Pakistani population is infected by HCV3a and number of patients enrolled in public and hospitals is increasing day by day. So there is a current need to develop a vaccine against HCV in particular to HCV3a that will cover approximately maximum Pakistani population. The current vaccines are DNA vaccine, Peptide vaccine and epitopic vaccines. Epitopes are the small antigenic segments of viral proteins and causes infections in the host. Epitopic vaccines provide more potent and controlled immune response and eliminates the potential lethal effects of the use of whole viral proteins [28]. Promiscuous epitopes (epitopes capable of binding maximum number of HLA alleles) may overcome the population coverage. Secondly the conserved epitopes reduces antigen escape associated with the viral mutation [29]. So the present study was designed for the prediction of promiscuous epitopes and to analyze their conservancy in general population. Any mutation in the peptide/epitope will lower the conservancy, so it was hypothesized to analyze the pI value of the mutated amino acid residue, that if remain in the range as was in original epitope provides the likeliness of that particular epitope to be used for epitopic vaccine design having an effective control over viral mutation, immune response with minimum side effects.

Methods

Sequence Retrieval and Analysis

The sequence of fully sequenced HCV 3a genome and protein of Pakistani origin was retrieved from NCBI [GU294484]. The number of individual bases in the genome i.e. the number of adenine; cytosine, guanine and thymine were calculated from DDBJ database. The molecular weight of proteins, percentage of highly repeated amino acid and the least repeated amino acid in the viral protein was calculated by using sequence and search analysis tool at PIR database (http://pir.georgetown.edu/).

Epitope Prediction

Promiscuous epitopes of HCV 3a viral proteins were predicted for HLA I and HLA II binding alleles using freely available immunoinformatics tools such as ProPred I, and ProPred respectively. In comparison to other epitope prediction tools, Propred 1 and Propred cover maximum number of Human Leukocyte antigens i.e. HLA and being used for epitopic prediction for HBV and tuberculosis. ProPred1 allows the user to predict antigenic apitopes for 47 MHC I alleles and ProPred allows epitopes prediction for 51 MHC II alleles. Predictions through these tools can be carried out at various thresholds from 1 to 10%. The algorithms designed for the working of these tools are based on linear coefficients of matrices. Maximum of the matrics were retrieved from BIMASS where the score of each peptide is calculated in multiplication and/or sum up manner. For example the score of following peptide "PACDPGRAA" can be calculated by using following equation:

Score = P(1) × A(2) × C(3) × D(4) × P(5) × G(6) × R(7) × A(8) × A(9)

Score = P(1) + A(2) + C(3) + D(4) + P(5) + G(6) + R(7) + A(8) + A(9)

Where P (1) is score of P at position 1.

Only the promiscuous epitopes with score higher than the chosen threshold score were assigned as predicted epitopes for the selected HLA alleles [30]. For the following study the default threshold i.e. 4% was used where the sensitivity and specificity are nearly the same for most of the HLA alleles available in ProPred1 and ProPred server. Moreover, MHC I alleles were predicted by keeping the proteosome and immunoproteosome filters on at 5% threshold because most of the MHC binders having a proteosomal cleavage site at C-terminal have higher likelihood to be T-cell epitopes [31]. The predicted promiscuous epitopes were positioned in the table in a decreasing order of their score.

Epitope Conservancy Analysis

All the predicted epitopes of HCV 3a proteins of Pakistani origin were subjected for worldwide conservancy analysis among HCV genotype 1, 2 and 3. 5 sequences against each HCV protein (used for epitope prediction) were retrieved from NCBI randomly. The predicted epitopes of HCV 3a (Pakistani origin) along with 5 selected sequences of individual genotypes (genotype 1, 2 and 3; one at a time) were submitted to epitope conservancy analysis tool available at IEDB database (http://tools.immuneepitope.org/tools/conservancy/iedb_input). All the epitopes having 77-100% conservancy were selected while rejecting the epitopes having variation at the anchor residues. The anchor residues in the predicted epitopes were highlighted by making it bold. The epitopes that were 100% conserved in the selected proteins of the 3 viral genotypes 1, 2 and 3 were also fully bold. Epitopes with 88/77% conservancy were with single or double amino acid variation respectively and to highlight them bold format was used in the conservancy column against each genotype.

Asteric sign (*) indicates that one out of five selected sequences either does not respond to epitope conservancy or have conservancy lower then 77%. Double asteric sign (**) indicates that only one sequence responds for 77-100% conservancy to the selected epitope.

Validation of varied amino acids using pI value

The Peptides with single or double amino acid variation were analyzed for their hydropathic characteristics or pI value [32]. The pI gives the information that the varied residue retained the amino acid group or diverted from its normal group in a particular peptide under consideration and thus provides information to be used or their rejection. All the varied amino acid residue with diverted group (with considerable change of pI value) were separated from other using superscript "D" for single variation and "DD" for diverted group for doubly varied residues. The superscript "D" in doubly varied residues of particular peptides represents the partial variation i.e. one of the varied residue retained the amino acid group while other residue shifted the amino acid group by a considerable change of pI value.

Results

HCV 3a genome of Pakistani origin comprises 9474 bp with GC content 2622 and 2700 respectively. The GC contents are 12.35% higher then AT contents. The genome encodes a polyprotein that subsequently get fragmented into structural and non structural protein of obvious molecular weight. The envelope protein E2 comprises highest moleculat weight 38755.3 KDa (Table 1). Leucine (L) a neutral nonpolar amino acid residue has the highest percent of repetition (13.1%) in E2 protein. The least repeated residue of E2 is a basic polar Lysine (K) (1.4%). The shortest segment viral protein is NS4a (5751.69 KDa molecular weight) comprising 54 amino acid residues. Leucine (L) and Valine (V) have highest percentage of repetition (14.8) and Histidine (H), Methionine (M), Threonine (T) and Tryptophan (W) are the least repeated amino acid residues (1.9%). The molecular weight of other viral proteins and percent repetition of their amino acid residue for were listed in Table 1. The percentage of amino acid residues gives an out look for their pI value and their probability of incidence in the antigenic epitopes.
Table 1

It comprises the data of HCV genome size, Proteins, Molecular weight and %age of highly repeated and least repeated amino acid residues in individual bases

Bases

No.

Proteins

aa Number

Mol. Wt.

Highly repeated aa

% of repetition

Least repeated aa

% of repetition

Total bp

9474

Capsid

114

12985.8

R

18.4

C/F

0.9

A

1974

Core

75

7638.88

L

16

E/K/M/Y

1.3

C

2700

E1

190

20643.9

V

11.1

E

1.1

G

2622

E2

350

38755.3

L

13.1

K

1.4

T

2178

NS3

149

15423.6

A/G

11.4

N

0.7

  

NS4a

54

5751.69

L/V

14.8

H/M/T/W

1.9

  

NS4b

194

20167.5

A

13.4

C

0.4

  

NS5a-1a

62

6700.72

G

14.5

E/D

1.6

  

NS5a-1b

101

11224.6

P

11.9

K/W

1

F (Phenylalanine), I (Isoleucine), L (Leucine), M (Methionine), V (Valine), W (Tryptophan) and Y (Tyrosine) were mainly the anchor residues for MHC II predicted epitopes and are nonpolar in nature. Total 150 epitopes were predicted against 51 alleles of MHC II (Table 2). The highest number of epitopes was represented by E2 protein comprising 20% of all MHC II predicted epitopes. VFLLNPCGL, FVILVFLLL, WHINSTVLH, FNLLDVPKA, LELINTHGS, VQYLYGVGS are the promiscuous binders of 45-50 MHC II alleles. E2 is followed by NS2 and NS4B proteins representing 14.66% of the predicted MHC II epitopes. In case of NS2 VRAHVLVRL, VILLTSLLY and VRLCMFVRS are the best binders both in term of score and the HLA allele coverage (50-51 MHC II alleles). FFNILGGWV, VNLLPAILS and VVNLLPAIL are the best binders of NS4b protein both in terms of HLA coverage (41 HLA coverage for the first epitope and 51 for the next 2 epitopes) and binding efficiency. LVVGVICAA, FNILGGWVA, WQKLEAFWH, IQYLAGLST and VVGVICAAL are also the epitopes of good quality covering 31 to 35 HLA alleles available in ProPred. For the NS5a_1a only three epitopes (MRLAGPRTC, FISCQKGYK and VVSTRCPCG) were predicted as promiscuous binders with the binding score higher then the selected threshold. Out of these three epitopes MRLAGPRTC is capable of binding all the HLA alleles available in ProPred server while FISCQKGYK and VVSTRCPCG bind 22 and 25 HLA alleles respectively. The predicted promiscuous binders against other proteins were also summarized in table 2.
Table 2

Predicted HLA II epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3 worldwide

Epitope start Position

Predicted T-cell epitopes

HLA alleles

HCV genotype 1

HCV Genotype 2

HCV Genotype 3

Capsid

     

43

L GVRATRKA

23

LGVRATRKTD

LGVRATRKT

LGVRATRKTD

36

L PRRGPRL G

15

LPRRGPRLG

LPRRGPRLG

LPRRGPRLG

106

W GPNDPRRR

16

WGPT DPRRR

WGPT DPRH RD

WGPNDPRRR

34

Y VLPRRGPR

24

YL LPRRGPR

YL LPRRGPR

YVLPRRGPR

21

V KFPGGGQI

8

VKFPGGGQI *

VKFPGGGQI

VKFPGGGQI

35

V LPRRGPRL

9

  

VLPRRGPRL

45

V RATRKASE

25

VRATRKT SED

VRATRKT SED

VRATRKT SED

30

V GGVY VLPR

39

VGGVYL LPR *

VGGVYL LPR

VGGVYVLPR

15

I RRPQDVKF

6

  

IRRPQDVKF

95

W LLSPRGSR

28

WLLSPRGSR

WLLSPRGSR

WLLSPRGSR

29

I VGGVYVLP

3

IVGGVYL LP *

IVGGVYL LP

IVGGVYVLP

82

W PLYGNEGC

10

WPLYGNEGC

WPLYGNEGC

WPLYGNEGC

85

Y GNEGCGWA

11

YGNEGCGWA

YGNEGCGWA *

YGNEGCGWA

33

V YVL PRRGP

1

VYL LPRRGP

VYL LPRRGP

VYVLPRRGP

Core

     

61

F LL ALLSCL

50

FLLALLSCL

FLLALLSCI

FLLALLSCL

64

L ALLSCLIH

45

LALLSCLTVDD

 

LALLSCLIH *

15

F ADLMGYIP

41

FADLMGYIP

FADLMGYIP

FADLMGYIP

24

L VGAPVGGV

44

LVGAPL GGA

 

LVGAPVGGV *

63

LL ALLSCLI

36

LLALLSCLTD

LLALLSCITD

LLALLSCLI *

62

FLL ALLSCL

24

FLLALLSCL

FLLALLSCI

FLLALLSCL *

32

V ARALAHGV

10

 

VARALAHGV

VARALAHGV

21

Y IPLVGAPV

28

YIPLVGAPL

YIPV VGAPL

YIPLVGAPV

19

M GYIPLVGA

26

MGYIPLVGA

MGYIPV VGA

MGYIPLVGA

E1

     

58

Y VGATTASI

41

  

YVGATTASI *

140

M VVAHILRL

39

  

MVVAHILRL*

2

W RNTSGLY V

27

  

WRNTSGLYV

138

V GM VVAHIL

28

   

56

V KY VGATTA

21

  

VR YVGATTAD *

9

Y VLTNARSN

31

  

YVLTNDC SNDD

161

W GVLAGLAY

15

WGVLAGM AY

WGVVF GLAY

WGI LAGLAY

93

F LVGQAFTF

11

FLVGQL FTF

 

FLVGQAFTF

181

I IMVMFSGV

91

  

IIMVMFSGV

130

M MMNWSPAV

35

MMMNWSPTAD

 

MMMNWSPAM

134

W SPAV GM VV

6

  

WSPAM GMVV *

132

M NW SPAV GM

14

  

MNWSPAM GM *

169

Y YTM QGNWA

18

  

YYS MQGNWA

47

W TPMTPTVA

21

  

WTPV TPTVA *

172

M QGNWAKVA

25

MV GNWAKVLD

MQGA WAKVID

WTPV TPTVAD *

145

I LRLPQTLF

19

  

ILRLPQTLF

E2

     

122

M LPHHRPVV

3

   

151

V FLLNPCGL

48

   

337

W EF VILVFL

4

  

WEFIV LVFL

339

F VIL VFLLL

46

  

FIV LVFLLL

35

W HINSTVLH

41

   

342

L VFLLLADA

 

LL FLLLADA

LL FLLLADA

LVFLLLADA

100

V LLAYAPRP

50

   

198

F RPLLPHRL

47

   

218

V RLGALVDT

12

   

62

F NLLDVPKA

45

   

26

L ELINTHGS

46

   

57

F YYHKF NLL

12

FYYHKFNSSD

 

FYYHKFNSTDD

83

V GPLDRCQH

26

   

58

Y YHKF NLLD

24

   

286

L LHSTTELA

17

LLHSTTEW A

 

LLHSTTELA

129

V VVGTTDPK

14

VVVGTTDKLDD

VVVGTTDRLDD *

VVVGTTDA K

320

V QYLYGVGS

46

VQYLYGVGS

 

VQYLYGVGS

159

L LVVGGLGG

14

   

293

L AILPCSFT

7

  

LAILPCSFT

335

L KWEF VIL V

4

  

LKWEFIV LV

322

Y LYGVGSGM

5

YLYGVGSSID

 

YLYGVGSGM

300

F TPMPALST

17

  

FTPMPALST

245

F YTVQGEDV

4

   

18

I VRGPEQRL

26

   

100

V LLAYAPRP

4

   

257

V WHRFTAAC

19

VE HRL TAACD *

  

206

L LQETSRGH

8

   

1

Y ITGGTAAR

8

   

267

W TRGERCDI

10

  

WTRGERCE I

310

I HLHQNIVD

11

IHLHQNIVD *

 

IHLHQNIVD

NS2

     

101

V RAHVLVRL

51

  

VRAHVLVRL

62

V ILLTSLLY

50

  

VILLTSLLY *

73

L VFDIAKLL

24

LVFDIT KLLD *

LVFDIT KLLD *

LI FDIT KLLD

153

L KDLAVATE

7

  

LKDLAVATE *

113

F VRSVTGGK

37

   

130

V GRWFNTYL

11

  

VGRWFNTYL *

123

F QMAILSVG

31

  

FQMI ILH VGD

137

Y LYDHLAPM

21

  

YLYDHLAPM

74

V FDIAKLLIA

23

VFDIT KLLL A D *

VFDIT KLLL AD

 

107

LV RLCMFVR

36

  

LVRLCML VR

108

V RLCMFVRS

51

  

VRLCML VRS *

89

YF VRAHV LV

33

  

YFVRAHVLV

11

IL VLFGFFT

15

   

37

Y AICRCESA

18

 

IIN GLPVSAD

YT ICRCESAD *

33

W WNQY AICR

8

  

WWNQYT ICRD

185

I LCGLPVSA

10

IIN GLPVSA *

IIN GLPVSA

ILCGLPVSA

145

M QHWAAAGL

18

  

MQHWAAAGL

50

V PPLLARGS

21

  

VPS LLARGSD *

88

LY LIQAAIT

35

  

LYLIQT AITD *

158

V ATEPVIFS

14

VAV EPVV FSD

VAV EPVV FS

VATEPVIFS

37

Y AICRCESA

19

  

YTICRCESAD *

175

W GADTAACG

11

WGADTAACG *

WGADTAACG *

WGADTAACG

NS3

     

4

V QVLSTATQ

46

VQIV STATQ

VQVLSSV TQD

 

43

L QMYTNVDQ

42

   

129

V CTRGVAKA

21

VCTRGVAKA

VCA RGVAKSDD *

 

24

W TVYHGAGS

13

WTVYHGAGT

WTVYHGAGN

 

84

VI PARRRGD

18

VIPV RRRGD *

  

138

L QF IPVETL

45

   

140

F IPVETLST

43

FIPVEN LG TD

  

6

V LSTATQTF

19

IV STATQTF

  

53

L VGWPAPPG

29

LVGWPAPQ G

LVGWPS PPGD

 

27

Y HGAGSRTL

22

YHGAGT RTI

  

14

F LGTTLGGV

10

   

77

L VTREADVI

25

LVTRH ADVI D *

LVTRN ADVID *

 

98

L SPRPLACL

12

 

LSPRPLST LD

 

124

IF RAAVCTR

44

   

NS4a

     

23

V VIVGHIEL

43

VVIVGR II LDD

VVIVGR IV LDD

VVIVGHIEL

3

W VLLGGVL AA

43

WVLV GGVLAA

WVLV GGVLAA

WVLLGGVLAA

4

V LL GGVL AAL

40

VLV GGVLAAL

VLV GGVLAAL

VLLGGVLAAL

38

V PDKEVLY Q

11

  

VPDKEVLYQ *

24

V IVGHI ELG

8

  

VIVGHIELG

10

L AALAAY CLS

8

LAALAAYCLT *

LAALAAYCLS

LAALAAYCLS

16

Y CLSVGCV V

6

 

YCLST GCVVD

YCLSVGCVV

26

V GHIELGGK

9

  

VGHIELGGK

25

I VGHIELGG

29

  

IVGHIELGG

20

V GCVVIVGH

15

  

VGCVVIVGH

9

VL AALAAY C

9

VLAALAAYC*

VLAALAAYC

VLAALAAYC

29

I ELGGKPAL

14

  

IELGGKPAL

NS4b

     

81

FF NILGGWV

41

  

FFNILGGWV

153

V NLLPAILS

51

VNLLPAILS

VNLLPAILS

VNLLPAILS

152

VV NLLPAIL

51

   

39

W NF VSGI QY

16

WNFI SGIQY

WNFI SGIQY

WNFVSGIQY

165

L VVGVICAA

35

LVVGVV CAA

LVVGVV CAA

LVVGVICAA

82

F NILGGWVA

32

FNILGGWVA

FNILGGWVA

FNILGGWVA

81

FF NILGGWV

5

  

FFNILGGWV

63

LM AFAASVT

9

LMAFT ASI TD

LMAFT AA VTDD

LMAFT ASVTD

27

W QKLEAFWH

35

 

WQKLEV FWAD

WQKLEAFWH *

167

V GVICAALL

11

VGVV CAAI L

VGVV CAAI L

VGVICAAI L

45

I QYLAGLST

35

IQYLAGLST

IQYLAGLST

IQYLAGLST

64

M AFAASVTS

23

MAFT ASI TS

MAFT AA VTSDD

MAFT ASVTSD

84

I LGGWVATH

24

ILGGWVAAQDD

ILGGWVAAQDD

ILGGWVATH

103

VV SGLAGAA

10

 

VGA GLAGAAD

VVSGLAGAA

166

VV GVICAAL

31

VVGVV CAAI

VVGVV CAAI

VGVICAAI L

85

L GGWVATHL

3

LGGWVAAQ LDD

LGGWVAAQ LDD

LGGWVATHL

60

V ASLMAFAA

15

  

VASLMAFT AD

41

F VSGI QYLA

8

FI SGIQYLA

FI SGIQYLA

FVSGIQYLA

139

F KIMGGELP

21

 

FKIMS GEV PD

FKIMGGEF P *

9

L QRATQQQA

14

  

LQRATQQQA *

122

L DILAGYGA

6

  

LDILAGYGA *

104

V SGLAGAAI

3

  

VSGLAGAAI

NS5a_1a

     

39

M RLAGPRTC

51

MRIV GPRTC *

FISCQKGYRD *

MRLAGPRTC*

3

F ISCQKGYK

22

FF SCQR GYKDD *

 

FISCQKGYK *

19

V VSTRCPCG

25

  

VM STRCPCG *

NS5a_1b

     

73

L LRDEITF V

20

LLRDEV TFQD*

LLRDEV TFQ D **

LLRDEITFV *

16

W RVAANSYV

33

WRVAAEE YVDD *

WRVAASE YVD

WRVAANSYV

55

F TEVDGVRL

4

FTEL DGVRL*

FTEVDGVRL **

FTEVDGVRL

80

FV VGLNSYA

25

  

FVVGLNSYA *

32

F HYITGATE

16

  

FHYITGATE

61

V RLHRYAPP

27

VRLHRYAPA*

 

VRLHRYAPP *

87

Y AIGSQLPC

20

YVV GSQLPC *

VRLHRYAPAD **

YAIGSQLPC *

23

YV EVRRVGD

14

YVEVT RVGDD *

YVEVT RVGDD **

YVEVRRVGD

Bold amino acid residues in T-cell Epitope column indicates the anchor residues

Bold individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope

*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%

** Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy

D Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value

DD Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value

Total 69 epitopes were predicted as promiscuous epitopes for MHC I alleles. The anchor residues in case of MHCI are quite varying both in amino acid residues and also in their nature. Mostly represented anchor residues are neutral nonpolar and neutral polar. However, quite small percentage of anchor residues were also acidic polar and basic polar in nature. The highest number of MHC I binding epitopes were represented by NS4b protein comprising 26% of all MHC I predicted epitopes. NFVSGIQYL epitope of NS4b is the best promiscuous binder of highest binding score. NS4b is followed by NS2, E2 and NS3 proteins representing 20.28% (NS2 epitopes) and 11.59% (for E2 and NS3). In case of NS2, 14 promiscuous epitopes were predicted with varying binding efficiency. GSRDGVILL, DGVILLTSL, WAAAGLKDL and LQVWVPPLL are the good binders both in term of score and the HLA allele coverage (21, 28, 27 and 28 alleles respectively). E2 predicted epitopes covers 20 to 28 HLA alleles except the PLLHSTTEL epitope that covers only 11 HLA alleles but with highest binding efficiency. NS3 epitopes covers 8 to 25 HLA alleles and were also ranked on the basis of their binding efficiency predicted by the score. The least represented epitopes were by NS5a_1a. It comprises only one epitope (HVKNGSMRL) as predicted promiscuous binders for 16 MHC I binding alleles. The promiscuous binders of MHC I for other proteins were also predicted and summarized in table 3.
Table 3

Predicted HLA I epitopes HCV Proteins of Pakistani origin and their conservancy in Genotype 1, 2 and 3 worldwide

Epitope start Position

Predicted T-cell epitopes

HLA alleles

HCV genotype 1

HCV Genotype 2

HCV Genotype 3

Capsid

     

38

R RGPRLGVR

9

RRGPRLGVR

RRGPRLGVR

RRGPRLGVR

35

V LPRRGPRL

25

  

VLPRRGPRL

Core

     

55

P GCSFSIFL

8

PGCSFSIFL

PGCSFSIFL

PGCSFSIFL *

41

R ALEDGINF

20

 

RV LEDGV NF **

RALEDGINF *

7

V IDTLTCGF

15

VIDTLTCGF

VIDTI TCGF *

VIDTLTCGF *

35

A LAHGVRAL

24

ALAHGVRV L

ALAHGVRVL

ALAHGVRAL *

24

L VGAPVGGV

18

LVGAPL GGA *

 

LVGAPVGGV *

26

G APVGGVAR

9

GAPL GGA AR *

GAPL GGVAR

GAPVGGVAR *

E1

     

135

S PAVGMVVA

14

  

SPAM GMVVA *

86

G DVCGAVFL

19

GDL CGS VFLD

GDVCGAVMI

GDM CGAVFL *

144

H ILRLPQTL

22

  

HILRLPQTL *

156

I AGAHWGVL

27

IAGAHWGVL

 

IAGAHWGI L

64

A SIRGHVDL

25

  

ASIRS HVDLD

E2

     

285

P LLHSTTEL

11

 

PLLHSTTEWD

PLLHSTTEL

305

A LSTGLIHL

25

ALT TGLIHL

 

ALSTGLIHL

227

C SFTPMPA L

20

CSFTTL PALD *

 

CSFTPMPAL

71

Q QLQAHHFL

27

   

157

C GLLVVGGL

28

   

212

R GHIQPVRL

24

   

6

T AARGGQGL

25

   

157

C GLLVVGGL

28

   

NS2

     

172

V ITWGADTA

6

  

VITWGADTA *

75

F DIAKLLIA

12

FDIT KLLL AD

FDIT KLLL AD *

FDIT KLLIAD

70

Y PSL VFDIA

15

  

YPSLI FDITDD

57

G SRDGVILL

21

GG RDA VILLD **

GG RDA VILLD *

GSRDGVILL

60

D GVILLTSL

26

  

DGVILLTSL *

148

W AAAGLKDL

27

 

WAAS GLR DLDD**

WAAAGLKDL *

50

V PPLLARGS

11

  

VPPLLARGS *

46

L QVWVPPLL

28

LH VWVPPLNDD

LH VWVPPLNDD *

LQVWVPPLL *

117

V TGGKYFQM

16

  

VV GGKYFQMD *

65

L TSLLYPSL

23

  

LTSLLYPSL

6

T LGAGILVL

48

  

TLGAGV LVL *

73

L VFDIAKLL

31

LVFDIT KLLD

LVFDIT KLLD *

LI FDIT KLLD

145

M QHW AAAGL

26

  

MQHWAAAGL

178

D TAACGDIL

21

DTAACGDII

DTAACGDIID *

DTAACGDIL

NS3

     

119

G HVAGIFRA

8

GHAV GIFRA *

GHVV GL FRA *

 

27

Y HGAGSRTL

14

YHGAGT RTI

YHGAGNK TLD

 

128

A VCTRGVAK

8

AVCTRGVAK

AVCTRGVAK *

 

57

P APPGAKSL

11

PAPQ GAR SLDD *

PS PPGT KSLDD

 

98

L SPRPLACL

25

 

LSPRPLST LD

 

95

A SLL SPRPL

24

   

130

C TRGVAKAL

20

CTRGVAKAV

  

7

L STATQTFL

24

   

NS4a

     

3

W VL LGGVLA

11

WVLV GGVLA

WVLV GGVLA

WVLLGGVLA

23

V VIVGHIEL

21

VVIVGR II LDD

VVIVGR IV LDD

VVIVGHIEL

10

L AALAAYCL

24

LAALAAYCL *

LAALAAYCL

LAALAAYCL

5

L LGGVL AAL

27

LV GGVLAAL

LV GGVLAAL

LLGGVLAAL

NS4b

     

96

P QSSSAFVV

6

  

PQSSSAFVV

40

N FVSGIQ YL

30

NFI SGIQYL

NFI SGIQYL

NFVSGIQYL

81

F FNIL GGWV

13

  

FFNILGGWV

46

Q YLAGLSTL

17

QYLAGLSTL

QYLAGLSTL

QYLAGLSTL

102

FV VSGLAGA

9

 

FVGA GLAGAD

FVVSGLAGA

54

L PG NPAVAS

14

LPGNPAI AS

LPGNPAI AS

LPGNPAVAS

161

S PGALVVGV

14

SPGALVVGV

SPGALVVGV

SPGALVVGV

141

I MGGELPNA

7

  

IMGGEF PT AD *

164

A LVVGVICA

11

ALVVGVV CA

ALVVGVV CA

ALVVGVICA

117

L GRVLLDIL

22

LGK VLV DILD*

LGK VLV DILD

LGK VLLDILD *

59

A VASLMAFA

9

AI ASLMAFTD

AI ASLMAFTD

AVASLMAFTD

152

V VNLLPAIL

15

   

113

G IGLGRVLL

24

  

GIGLGK VLLD *

56

G NPAVASLM

12

GNPAI ASLM

GNPAI ASLM

GNPAVASLM

52

S TLPGNPAV

21

STLPGNPAI

STLPGNPAV

STLPGNPAV

85

L GGWVATHL

26

LGGWVAAQ LDD

LGGWVAAQ LDD

LGGWVATHL

145

E LPNAEDVV

11

   

99

S SAFVVSGL

22

  

SSAFVVSGL

NS5a_1a

     

33

H VKNGSMRL

16

HVKNGSMRI *

HVKNGSMRI **

HVKNGSMRL

NS5a_1b

     

49

V PAAEFFTE

6

VPAP EFFTE *

VPAP EFFTE **

VPAAEFFTE

79

T FVVGLNSY

10

TFQ VGLNQ YD *

TFT VGLNSFD *

TFT VGLNSYD *

76

D EITFVVGL

19

DEV TFQ VGLD *

DEV TFT VGLD*

DEITFM VGL *

Bold amino acid residues in T-cell Epitope column indicates the anchor residues

Bold individual amino acid residues in HCV Genotype 1, 2 and 3 columns indicated the variation in peptide in comparison to the predicted epitope

*Indicates that one of the protein sequence selected for epitope conservancy either does not respond or have conservancy lower then 70%

** Indicates that only one of the protein sequence from selected sequences respond to epitope conservancy

D Indicates that amino acid residue in case of single/double variation diverted their group compared to primary epitope using pI value

DD Indicates that both amino acid residues in case of double variation diverted their group compared to primary epitope using pI value

Out of total 150 predicted MHC II epitopes, 75.33% were (77-100%) conserve in genotype 3 (Table 1) against the randomly selected viral proteins. Out of 75.33% conserved peptides of genotype 3, 71.68% peptides were 100% conserve while 22.12% peptides were having single residue variation (88% epitope conservancy). Only the 40% peptides of singly varied residues diverted their amino acid group and the pI value while 60% singly varied residues retained the amino acid group as was in the predicted epitope of HCV 3a proteins. 6.19% peptides comprised the 77% epitope conservancy because of double residue variation in the peptides of general population in contrast to predicted epitopes of HCV 3a of Pakistani origin. Out of 6.19%, doubly varied amino acid residues 42.85% peptides retained their amino acid group and nearly same pI value as in case of predicted epitope while 28.57% peptides were having partial group divertion and 28.57% (of doubly varied amino acid residues) peptides diverted their amino acid group because of considerable variation in the pI value. Similar data was also obtained for the HCV genotype 1 and 2 consisting 47.33% and 40.66% conservancy respectively. However, in contrast to genotype 3, only 23.94% predicted epitopes were 100% conserve in randomly selected sequences of genotype 1 and 22.95% in genotype 2. Their rate of single/double residue variation was also predicted and expressed as figure 1.
Figure 1
Figure 1

A comparative analysis of HCV 3a Predictive epitopes against MHC II alleles and their conservancy analysis in Genotype 1, 2 and 3 worldwide.

Out of total 69 predicted MHC I epitopes, 78.26% were (77-100%) conserve in genotype 3 (Table 2) against the randomly selected viral proteins. Out of 78.26% conserved peptides of genotype 3, 72.22% peptides were 100% conserve while 22.22% peptides were having single residue variation (88% epitope conservancy). 40.66% peptides of singly varied residues retained the amino acid group as was in the predicted epitope of HCV 3a proteins while 58.33% singly varied residues diverted their amino acid group and the pI value. 5.5% peptides comprised the 77% epitope conservancy because of double residue variation in the peptides of general population in contrast to predicted epitopes of HCV 3a of Pakistani origin. Out of 5.5%, doubly varied amino acid residues 66.66% peptides were having partial group divertion and 33.33% (of doubly varied amino acid residues) peptides diverted their amino acid group because of considerable variation in the pI value. Similar data was also obtained for the HCV genotype 1 and 2 consisting 55.07% conservancy. However, in contrast to genotype 3, only 21.05% predicted epitopes were 100% conserve in randomly selected sequences of genotype 1 and 2. Their rate of single/double residue variation was also predicted and expressed as figure 2.
Figure 2
Figure 2

A comparative analysis of HCV 3a Predictive epitopes predicted against MHC I and their conservancy analysis in Genotype 1, 2 and 3 worldwide.

Discussion

The modern technique for control of HCV infection is a vaccine preparation that can specifically induce antibody-mediated immunity. The rapid advancements in the computational methodologies and immunoinformatics/immuno-bioinformatics provide new strategies for the synthesis of antigen specific epitopic vaccine against infectious agents such as viruses and pathogens. Epitopic vaccine against HIV, malaria and tuberculosis provided promising results and supported the defensive and therapeutic uses of these vaccines [33]. Thus in the present study, a new systematic immunoinformatics approach was applied for the predicted antigenic epitopes of HCV 3a proteins of Pakistani origin followed by diversity and conservancy in other genotypes (1,2 and 3) in randomly selected HCV sequences from NCBI and mainly belong to Thailand, Cuba, UK, USA, China, Japan, France, Italy and Germany. The immunogenic epitopes identified were nanomers and could be used diagnostically to detect HCV specific CTL responses in the patients and after vaccination. A CTL based HCV vaccine might not efficient enough to prevent from infection but it might protect the body from the disease. The analysis showed that the minimal number of epitopes required to represent the complete anigenicity of the whole proteins are significantly smaller then required to represent full length proteins. The majority of the epitopes reported here had intermediate to high HLA binding affinity.

By the use of an efficient CTL based epitope delivery technology; the predicted epitopes could eventually become vaccines in their own or fused as polytopes. The design of the HCV vaccine using conserved epitopes can avoid viral mutation and thus provides more efficient results. The study shows that the predicted epitopes were highly conserved in HCV genotype 3 and also but less conserved in genotype 1 and 2 both for MHC I and MHC II. Moreover, to ensure the viral detection at all stages of its intracellular evolution we have used all the viral proteins. Therefore, the total number of predicted epitopes were also maximized in correspond to the number of covered proteins used for the analysis.

Abbreviations

HCV: 

hepatitis C virus

HLA: 

human leukocyte antigen

MHC: 

major histocompatability complex

CTL: 

cytotoxic T lymphocytes.

Declarations

Authors’ Affiliations

(1)
Bioinformatics Division Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
(2)
Division of Molecular Virology Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

References

  1. Qi R, Zhang L, Chi C: Biological characteristics of dengue virus and potential targets for drug design. Acta Biochim Biophys Sin 2008, 40: 91-101. 10.1111/j.1745-7270.2008.00382.xView ArticlePubMedGoogle Scholar
  2. Blitvich JB, Fernandez-Salas I, Contreras-Cordero FJ, Marlenee LN, Gonzalez-Rojas IJ, Komar N, Gubler JD, Calisher HC, Beaty JB: Serologic Evidence of West Nile Virus Infection in Horses, Coahuila State, Mexico. Emerging Infectious Diseases 2003,9(7):853-856.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Moennig V: Introduction to classical swine fever: virus, disease and control policy. Veterinary Microbiology 2000, 73: 93-102. 10.1016/S0378-1135(00)00137-1View ArticlePubMedGoogle Scholar
  4. Stiffler DJ, Nguyen M, Sohn AJ, Liu C, Kaplan D, Seeger C: Focal Distribution of Hepatitis C Virus RNA in Infected Livers. PLoS ONE 2009,4(8):1-7. 10.1371/journal.pone.0006661View ArticleGoogle Scholar
  5. Raja SN, Janjua AK: Epidemiology of hepatitis C virus infection in Pakistan. J Microbiol Immunol Infect 2008, 41: 4-8.PubMedGoogle Scholar
  6. Raja SN, Singh NN, Janjua AK, Najam-Ul-Haq R: Hepatitis C virus infection: An enigma continues. Medicine Today 2006,4(3):93-101.Google Scholar
  7. Das RB, Kundu B, Khandapkar R, Sahni S: Geographical distribution of hepatitis C virus genotype in India. Indian J Pathol Microbiol 2002,45(3):323-328.PubMedGoogle Scholar
  8. Rychłowska M, Bieńkowska-Szewczyk K: Hepatitis C- new developments in the studies of the viral life cycle. Acta Biochimica Polonica 2007,54(4):703-715.PubMedGoogle Scholar
  9. Jobarteh Modou, Malfroy Marine, Peterson Ingrid, Jeng Adam, Ramu Sarge-Njie, Alabi Abraham, Peterson Kevin, Cotten Matt, Hall Andrew, Sarah Rowland-Jones, Whittle Hilton, Tedder Richard, Jaye Assan, Mendy Maimuna: Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virology Journal 2010, 7: 230-239. 10.1186/1743-422X-7-230PubMed CentralView ArticlePubMedGoogle Scholar
  10. Re DV, Caggiari L, Vita DS, Mazzaro C, Lenzi M, Galli M, Monti G, Ferri C, Zignego LA, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Cannizzaro R, Guidoboni M, Dolcetti R: Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Digestive and Liver Disease 2007,39(1):65-71.View ArticleGoogle Scholar
  11. Wazir I, Wazir F, Javed M, Saeed M, Najeeb-ul-Haq Khan H: Effect of vitamin "e" supplements in herapy of chronic hepatitis c: a histological study. Gomal Journal of Medical Sciences 2008,6(2):81-86.Google Scholar
  12. Jia Y, Wei L, Jiang D, Wang J, Cong X, Fei R: Antiviral action of interferon-α against hepatitis C virus replicon and its modification by interferon-γ and interleukin-8. J Gastroenterology and Hepatology 2007, 22: 1278-1285. 10.1111/j.1440-1746.2007.04957.xView ArticleGoogle Scholar
  13. Yoon JE, Hu K: Hepatitis C Virus (HCV) Infection and Hepatic Steatosis. Int J Med Sci 2006,3(2):53-56.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Minakari M, Sameni KF, Shalmani MH, Molaee M, Zali M: Hepatic Steatosis in Iranian Patients with Chronic Hepatitis C. Med Princ Pract 2008, 17: 126-130. 10.1159/000112966View ArticlePubMedGoogle Scholar
  15. Zubair A, Jamal S, Mubarik A: Morphometric Analysis of Hepatic Steatosis in Chronic Hepatitis C Infection. The Saudi Journal of Gastroenterology 2009,15(1):11-4. 10.4103/1319-3767.45047View ArticlePubMedGoogle Scholar
  16. Ali Amjad, Habib Ahmad, Ali Ijaz, Sheema Khan, Gulshan Zaidi, Muhammad Idrees: Prevalence of active hepatitis c virus infection in district mansehra Pakistan. Virology Journal 2010, 7: 334-338. 10.1186/1743-422X-7-334PubMed CentralView ArticlePubMedGoogle Scholar
  17. Ramia S, Eid-Fares J: Distribution of hepatitis C virus genotypes in the Middle East. International Journal of Infectious Diseases 2006, 10: 272-277. 10.1016/j.ijid.2005.07.008View ArticlePubMedGoogle Scholar
  18. Ali Amjad, Habib Ahmed, Muhammad Idrees: Molecular epidemiology of Hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan. Virology Journal 2010, 7: 203-209. 10.1186/1743-422X-7-203PubMed CentralView ArticlePubMedGoogle Scholar
  19. Idrees M, Riazuddin S: Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infectious Diseases 2008,8(69):1-9. 69Google Scholar
  20. Lauer G, Walker B: Hepatitis C V Irus Infection. N Engl J Med 2001,345(1):41-52. 10.1056/NEJM200107053450107View ArticlePubMedGoogle Scholar
  21. Jawaid A, Khuwaja KA: Treatment and Vaccination for Hepatitis C: Present and Future. J Ayub Med Coll 2008,20(1):129-133. AbbottabadGoogle Scholar
  22. Pan Q, Henry DS, Metselaar JH, Scholte B, Kwekkeboom J, Tilanus WH, Janssen ALH, Laan WJL: Combined antiviral activity of interferon- α and RNA interference directed against epatitis without affecting vector delivery and gene silencing. J Mol Med 2009, 87: 713-722. 10.1007/s00109-009-0470-3PubMed CentralView ArticlePubMedGoogle Scholar
  23. Gozlan J, Lacombe K, Gault E, Raguin G, Girard P: Complete cure of HBV-HDV co-infection after 24 weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV/HCV/HDV/HIVq. Journal of Hepatology 2009, 50: 432-434. 10.1016/j.jhep.2008.05.029View ArticlePubMedGoogle Scholar
  24. Tan Lei, Lu Huijun, Dan Zhang, Mingyao Tian, Hu Bo, Wang Zhuoyue, Jin Ningyi: Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes. Virology Journal 2010, 7: 363-376. 10.1186/1743-422X-7-363PubMed CentralView ArticlePubMedGoogle Scholar
  25. Reche AP, Reinherz LE: PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Research 2005, 33: 138-142. 10.1093/nar/gki357View ArticleGoogle Scholar
  26. Zhang LG, Khan MA, Srinivasan NK, August TJ, Brusic V: MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides. Nucleic Acids Research 2005, 33: 172-179. 10.1093/nar/gki452View ArticleGoogle Scholar
  27. Robinson LH, Amara RR: T cell vaccines for microbial infections. Nature Medicine Suppliment 2005,11(4):25-32. 10.1038/nm1212View ArticleGoogle Scholar
  28. Groot DSA, Sbai H, Aubin SC, Mcmurry J, Martin W: Immuno-informatics: Mining genomes for vaccine components. Immunology and Cell Biology 2002, 80: 255-269. 10.1046/j.1440-1711.2002.01092.xView ArticlePubMedGoogle Scholar
  29. Lund O, Nielsen M, Kesmir C, Petersen GA, Lundegaard C, Worning P, Sylvester-Hvid C, Lamberth K, Røder G, Justesen S, Buus S, Brunak S: Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004,55(12):797-810. 10.1007/s00251-004-0647-4View ArticlePubMedGoogle Scholar
  30. Singh H, Raghava SPG: ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003,19(8):1009-1014. 10.1093/bioinformatics/btg108View ArticlePubMedGoogle Scholar
  31. Somvanshi P, Singh V, Seth KP: In Silico Prediction of Epitopes in Virulence Proteins of Mycobacterium Tuberculosis H37Rv for Diagnostic and Subunit Vaccine Design. Journal of Proteomics & Bioinformatics 2008,1(3):143-153.View ArticleGoogle Scholar
  32. Kyte J, Doolittle FR: A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 1982,157(1):105-132. 10.1016/0022-2836(82)90515-0View ArticlePubMedGoogle Scholar
  33. Khan MA, Miotto O, Heiny TA, Salmon J, Srinivasan NK, Nascimento MJE, Marques JETA, Brusic V, Tan WT, August TJ: A systematic bioinformatics approach for selection of epitope-based vaccine targets. Cellular Immunology 2006, 244: 141-147. 10.1016/j.cellimm.2007.02.005PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Shehzadi et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Virology Journal

ISSN: 1743-422X